Former President of the College of Naturopathic Physicians of British Columbia Joins StillCanna’s Team

Vancouver, British Columbia – (PR Newswire) – Thursday, May 16, 2019 – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce that Dr. Brian Martin, ND has joined the StillCanna Team. Dr. Martin brings a wealth of knowledge and experience, including but not limited to:

  • 25 years practicing Naturopathic Medicine;
  • the formulation of innovative natural health products;
  • former President of the College of Naturopathic Physicians of British Columbia; and
  • Expert in Optimal Aging from the American Academy of Anti-Aging Medicine.

Dr. Martin will lead the Company’s consumer and Nutraceutical and Cosmeceutical product formulations with the goal of enhancing the natural capabilities of CBD and other therapeutic cannabinoids, including terpenes and other organic compounds. He will be the Company’s medical representative for industry research, speaking engagements and product formulations. Dr. Martin will evaluate the current Olimax product line and expects to formulate new CBD related products with a special focus on the expanding nutritional (food and beverages) and wellness marketplaces. Particular attention will be directed towards the female market, along with matters related to the improvement of quality of life, including products aiming to enhance energy, mood, memory, libido and athletic performance.

“Dr. Martin has dedicated his life to the proactive empowerment of the modern consumer, and has developed substantial practical experience and knowledge of the current health needs of both men and women” exclaimed Jason Dussault Chief Executive Officer of StillCanna. “We anticipate that his practical knowledge and capabilities will make StillCanna’s CBD products increasingly effective and metabolically friendly compared to other products currently available in the market. Dr. Martin will work with the Company part time for the next 2 quarters with an eye towards full time employment as we expand our product vision.”

“I have been very impressed with some of the proprietary techniques and technologies StillCanna has relating to the production and formulation of various CBD products,” stated Dr. Martin. “StillCanna’s vision of CBD in the wellness and the global Nutraceutical market is in line with the types of CBD products I envision. StillCanna’s CEO has strong branding and marketing skills which, coupled with my formulation skills, paints a very exciting picture.”

As partial compensation for the engagement of Dr. Martin, the Company will grant 200,000 incentive stock options to Dr. Martin with an exercise price equivalent to a 5% premium to the closing price of the Company’s common shares on the date of grant.

Further to its press release dated May 7, 2019, the Company has also issued 850,000 common shares to certain finders in connection with the acquisition of Olimax. As a result, an aggregate of 1,300,000 common shares have been issued to finders in connection with the acquisition of Olimax.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.

 On Behalf of the Board,
Jason Dussault,
Chief Executive Officer and Director
Email: info@stillcanna.com
Phone: 604-239-0840

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the enhancement of the natural capabilities of CBD and other therapeutic cannabinoids, the formulation of new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, the increased effectiveness and metabolic friendliness of the Company’s products and the hiring of Dr. Martin as a full time employee of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will be able to hire Dr. Martin as a full time employee of the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will not be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will not be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will not be able to hire Dr. Martin as a full time employee of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Leave a Reply

Your email address will not be published. Required fields are marked *

Going Public

As of November 16, 2018

We have filed our listing statement in connection with EVI Global Group Developments Corp.’s change of business with the CSE for comments.

Timeline

16May, 2019

Former President of the College of Naturopathic Physicians of British Columbia Joins StillCanna’s Team

read more

7May, 2019

Stillcanna Acquires Polish Hemp Producer and Receives the Proceeds of Its $24,365,000 Financing

read more

30Apr, 2019

StillCanna Begins Hemp Initiative in Poland

read more

25Apr, 2019

StillCanna Closes Oversubscribed Private Placement of Subscription Receipts for $24,365,000

read more

11Apr, 2019

StillCanna Recruits Seasoned PhD to Manage Its Romanian Extraction Facility and Provides Update on Its Previously Announced Financing

read more

28Mar, 2019

StillCanna Signs C$6 Million Per Month Agreement with California Based BioScience Enterprises, Inc. to Supply CBD

read more

18Mar, 2019

StillCanna Signs Definitive Agreement for the Acquisition of a Leading European Hemp Cultivator Olimax

read more

15Mar, 2019

StillCanna’s Anchor Extraction Customer Increases Its Monthly Order By Over 300%

read more

15Mar, 2019

EVI Global Group Developments Corp. (CSE: EVI) Changes to StillCanna Inc. (CSE: STIL), a Leading Extractor of CBD in Europe, and Begins Resumption of Trading

read more

19Feb, 2019

EVI’s European Based Extraction Facility Initiates Hemp Processing

read more

15Oct, 2018

EVI Global firms up acquisition of Borganic Consulting

read more

11Oct, 2018

EVI Global Group closes $4-million private placement

read more

6Sep, 2018

EVI Global Group to acquire Borganic Consulting

read more

Refinery #1 - Romania

June 7, 2018

LEASED FACILITY IN ROMANIA

June 7, 2018

COMPLETED FACILITY ENGINEERING DRAWINGS

August 1, 2018

ORDERED CUSTOM MANUFACTURED EQUIPMENT AND SCIENTIFIC EQUIPMENT

June 7, 2018

LEASED FACILITY IN ROMANIA

September 1, 2018

HIRED LOCAL ARCHITECT FOR PERMITTING

September, 2018

FLOORS, WASHROOMS, WALLS, ROOF AND CEILING ALL IMPROVED

October 1, 2018

LARGE HEMP SEPARATOR MACHINE ARRIVES ON SITE

November 15, 2018

ROMANIAN SUBSIDIARY COMPANY DOCUMENTS APPROVED & REGISTERED

November 22, 2018

ROMANIAN STAFFING PROCESS STARTED - FACILITY GM HIRED

November 25, 2018

SUCCESSFUL SITE VISIT OF GOVERNMENTAL ENVIRONMENTAL AGENCY

November 25, 2018

BAILESTI MAYOR VISIT - HEAVILY SUPPORTIVE

December 1, 2018

PLACED TWO 40 FOOT CONTAINERS AT FACILITY FOR STORAGE

December 5, 2018

FOUR CONTAINERS OF SPECIALIZED EQUIPMENT ARRIVED FROM SUPPLIERS FORKLIFT ARRIVED

  • Anticipated Upcoming Milestones
June 7, 2018

LEASED FACILITY IN ROMANIA

December 15, 2018

ASSEMBLY OF SEPARATOR MACHINE, GENERAL MANAGER HIRING STAFF FOR JAN 2019 START

December 20, 2018

COMPLETION OF 40 FOOT WALK IN FREEZER

January 1, 2018

COMPLETION OF INTERIOR WALLS AND SECURITY SYSTEMS

January 7, 2018

INSTALLATION OF SCIENTIFIC EQUIPMENT

January 21, 2018

BEGIN EXTRACTION

Update on Our Partners

Milestones

April, 2017

planted first crop

May, 2017

obtained first licence to grow

June, 2017

purchased first 10ha of land

September, 2017

commenced first run of finance

November, 2017

Closed first run of finance

January, 2018

extraction of first crop

February, 2018

dragonfly product online

March, 2018

open loan note

May, 2018

EIS status granted

July, 2018

3yr gmp licence granted

August, 2018

signed ceuta as a distributor

August, 2018

commenced second harvest

September, 2018

cbd content crop analysis 7.58%

September, 2018

J/V melabies

September, 2018

first bulk sale order (germany)

October, 2018

season 2 harvest completed

October, 2018

sale to day lewis pharmacy

October, 2018

starpharma

November, 2018

closed loan note

November, 2018

boots istribution deal

Industry News

15Oct, 2018

EVI Global firms up acquisition of Borganic Consulting

EVI ANNOUNCES PROPOSED ACQUISITION OF BORGANIC CONSULTING INC. In connection with the letter of intent with Borganic Consulting Inc. previously announced on Sept. 6, 2018, EVI Global Group Developments Corp. has entered into a definitive share exchange agreement with Borganic under which the company has agreed to acqui...Read More

11Oct, 2018

EVI Global Group closes $4-million private placement

EVI ANNOUNCES CLOSING OF OVERSUBSCRIBED NON-BROKERED PRIVATE PLACEMENT EVI Global Group Developments Corp. has closed its non-brokered private placement previously announced on Sept. 5, 2018. Due to increased demand, the previously announced private placement was increased from $3-million to $4-million with 16 million ...Read More